These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 35651605)

  • 21. Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment.
    Dain L; Zhu G
    Int J Pharm; 2023 May; 638():122924. PubMed ID: 37037396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
    Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
    Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
    Sattiraju A; Mintz A
    Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy.
    Kudruk S; Forsyth CM; Dion MZ; Hedlund Orbeck JK; Luo J; Klein RS; Kim AH; Heimberger AB; Mirkin CA; Stegh AH; Artzi N
    Proc Natl Acad Sci U S A; 2024 Feb; 121(8):e2306973121. PubMed ID: 38346200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for Neuro-Oncology.
    Majd N; Dasgupta P; de Groot J
    Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
    Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
    J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
    Pang L; Khan F; Heimberger AB; Chen P
    Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
    Liu Y; Zhou F; Ali H; Lathia JD; Chen P
    Cell Mol Immunol; 2024 Dec; 21(12):1354-1375. PubMed ID: 39406966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
    Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
    Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
    Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives.
    Abadi B; Yazdanpanah N; Nokhodchi A; Rezaei N
    Adv Drug Deliv Rev; 2021 Dec; 179():114035. PubMed ID: 34740765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. γδ T cells as a potential therapeutic agent for glioblastoma.
    Kang I; Kim Y; Lee HK
    Front Immunol; 2023; 14():1273986. PubMed ID: 37928546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Interplay between Glioblastoma and Its Microenvironment.
    Dapash M; Hou D; Castro B; Lee-Chang C; Lesniak MS
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
    Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
    Front Immunol; 2022; 13():820673. PubMed ID: 35309323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current State of Immunotherapy for Treatment of Glioblastoma.
    McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
    Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable.
    Barzegar Behrooz A; Talaie Z; Syahir A
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.
    Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F
    Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
    Miyazaki T; Ishikawa E; Sugii N; Matsuda M
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.